NBIS vs PFE: Which Is the Better Buy?
Side-by-side comparison of Nebius Group N.V. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
Nebius Group N.V. · Technology
$218.99
+11.9% upside to fair value
Med Conviction
Grade C+
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
NBIS has more upside to fair value
(+11.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NBIS |
PFE |
| Current Price |
$218.99 |
$25.22 |
| Fair Value Estimate |
$245.00 |
$25.92 |
| Upside to Fair Value |
+11.9%
|
+2.8%
|
| Market Cap |
$52.6B |
$143.7B |
| Forward P/E |
—
|
19.2x
|
| EV / EBITDA |
—
|
12.3x
|
| Price / Sales |
59.9x
|
2.3x
|
| Price / FCF |
—
|
15.2x
|
| Revenue Growth YoY |
+684.0%
|
+5.4%
|
| Gross Margin |
48.0%
|
69.3%
|
| Operating Margin |
-68.8%
|
23.4%
|
| Return on Equity |
—
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
-4.7%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Nebius Group is a fast-scaling neocloud GPU infrastructure provider spun out of Yandex's international assets, positioned at the center of the AI compute buildout with a validated capital relationship to Nvidia, which holds a 9.3% stake following a $2 billion investment. Revenue grew 684% year over year in Q1 2026 to $399 million, core AI cloud ARR reached $1.92 billion, and the company has locke…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
NBIS |
PFE |
| Zone Low |
$184.00 |
$19.44 |
| Zone High |
$208.00 |
$22.03 |
| In Buy Zone? |
No
|
No
|